Navigation Links
ACRES Names Katherine Madigan VP for Global Alliances and Advocacy
Date:11/30/2013

(PRWEB) November 30, 2013

ACRES, the Alliance for Clinical Research Excellence and Safety, a collaborative non-profit organization building a global system for clinical research, has named Katherine Madigan, MHSA, as its new Vice-President for Global Alliances and Advocacy.

Ms. Madigan brings in-depth knowledge of the clinical research enterprise and organizational development to ACRES. She previously led the Association of Clinical Research Organizations (ACRO) as Senior Vice President, where she directed the business operations and international lobbying activities on behalf of the global clinical outsourcing industry.

Prior to ACRO, she served as Director of Government Affairs & Special Projects at the Association of Clinical Research Professionals (ACRP), an ACRES strategic ally, founding the organization’s government affairs practice and focusing on international coalition building. Madigan concurrently served as Managing Director of the Academy of Physicians in Clinical Research, an ACRP affiliate, responsible for governance and strategic development for the physician-only organization. Her experience also includes public policy analysis and development in the office of Robert Merrifield, member of the Canadian Parliament, where she developed drug safety initiatives for Health Canada, and in 2001 she studied public opinion of stem cell research within the Office of the Agency Liaison at The White House under President George W. Bush.

“We are thrilled to have Ms. Madigan join the ACRES leadership team”, said Dr. Greg Koski, ACRES President and CEO. “An individual with the unique range of experiences in public policy, regulatory affairs, organizational m
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Clinical Research Site-Expert Johan Karlberg to Lead ACRES Global Network Development
2. ACRES and PharmaTrain Announce Strategic Alliance
3. ACRES Announces Strategic Alliance with Atlantis Global Research Institute
4. ACRES Launches Global Clinical Research Network Technology Platform
5. ISPE Names Dr. Thomas Zimmer as Vice President of European Operations
6. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
7. Vaccinogen Names Dr. Benjamin Carson and Dr. Jan B. Vermorken to Medical Advisory Board
8. Biosimilars Need Same Names as Original Biologics, Hospira Says at World Health Organization (WHO) Meeting
9. Genera Energy Names Sam Jackson VP of Business Development
10. Adheron Therapeutics Names New Senior Leadership
11. Golden West Biologicals Names Matriks as Distribution Partner in Norway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed unknowingly to ... time period, doctors did not know that they needed to ... of vulnerable patients. In the same way, medical interns and ... transmitting herpes viruses to their patients. The CBCD explains. , ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... BRISBANE, Calif., Aug. 7 InterMune, Inc. (Nasdaq: ... and President of InterMune, will present at the Canaccord Adams 29th ... 10:30 a.m. EDT. , , To access a ... may log on to the investor relations page of InterMune,s corporate ...
... YORK, Aug. 7 /PRNewswire-Asia-FirstCall/ -- , , ... --2Q09 Net Income Attributable to Controlling Interest was $13.2 million or , ... $0.17 per Diluted Share--, ... American Oriental Bioengineering, Inc. (NYSE: AOB ), ("the Company" or,"AOBO"), ...
... , , EMERYVILLE, Calif., Aug. 6 ... it has agreed to sell an aggregate of four million shares of ... share and $200 million aggregate principal amount of its 4.00% convertible senior ... the underwriters 30-day options to purchase up to an additional 600,000 shares ...
Cached Biology Technology:American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 2American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 3American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 4American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 5American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 6American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 7American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 8Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 2Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 3
(Date:4/17/2014)... fish consumption advisories for expecting mothers are ineffective ... persistent organic pollutants (POPs). , The study, ... of Toronto Scarborough PhD student Matt Binnington and ... of environmental contamination, a mother,s compliance with advisories, ... influenced exposure in her children. , Their model ...
(Date:4/17/2014)... University engineer has developed a patented technique that ... devices. The same technique could help police during ... and Kay L. Theede chair in engineering and ... his research team have created a template-based system ... trunks. The distance detection method called stand-off ...
(Date:4/17/2014)... and pathogens that devastate honeybees in Europe, Asia and ... do not appear to be impacting native honeybee populations ... researchers., The invasive pests include including Nosema microsporidia ... honeybees appear to be resilient to these invasive pests, ... control pests in Europe, Asia and the United States ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... soon be able to make pest insects buzz off for ... all thanks to a tiny finding with enormous potential. ... Pune, India, is the senior author of a study that ... National Academy of Sciences , also called PNAS. Her work ...
... the University of Leeds have come a step closer to ... Their findings, published in the International Journal of Cancer ... to tackle other cancers should be considered as a future ... tamoxifen, that target a protein responsible for tumour growth, have ...
... , This release is available in German ... geneticists no longer dismiss out of hand his belief that ... published his book on evolution, Lamarck,s theory of transformation went ... decade, we have learned that the environment can after all ...
Cached Biology News:From protein to planes and pigskin 2From protein to planes and pigskin 3Another step toward resisting breast cancer 2Epigenetic changes don't last 2Epigenetic changes don't last 3Epigenetic changes don't last 4
supplied with 10x reaction buffer...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
... BioPrime Plus Array CGH Genomic Labeling Systems ... reproducible labeling of genomic DNA samples for ... both indirect and direct labeling formats, the ... provide a flexible solution to your genomic ...
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
Biology Products: